Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16995333,t(max),"The 90% non-parametric confidence interval for the median t(max) of almotriptan plus ethanol compared to almotriptan alone (0.61/2.72) was outside the acceptable range (0.70 - 1.30), demonstrating that concomitant ethanol administration slightly increases the variability of absorption of almotriptan 12.5 mg.","Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995333/),,0,21891,DB00918,Almotriptan
,15386481,elimination half-life,The elimination half-life was constant at approximately 3 h across all dose levels.,Pharmacokinetics and safety of oral almotriptan in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386481/),h,3,26036,DB00918,Almotriptan
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],483,90332,DB00918,Almotriptan
,11422001,AUC,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[h·ng] / [ml],352,90333,DB00918,Almotriptan
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],26.6,90334,DB00918,Almotriptan
,11422001,oral clearance,"Mean almotriptan AUC was higher (483 +/- 99.9 vs 352 +/- 75.4 ng ml-1 h, P = 0.0001) and oral clearance was lower (26.6 +/- 4.00 vs 36.6 +/- 5.89 l h-1, P = 0.0001) when almotriptan was administered with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),[l] / [h],36.6,90335,DB00918,Almotriptan
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,4.22,90336,DB00918,Almotriptan
,11422001,half-life,"Mean half-life was longer (4.22 +/- 0.78 vs 3.41 +/- 0.45 h, P = 0.0002) after coadministration with moclobemide.","Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422001/),h,3.41,90337,DB00918,Almotriptan
,11210405,Cmax,"Mean almotriptan Cmax was significantly higher following combination treatment with fluoxetine (52.5 +/- 11.9 ng/ml vs. 44.3 +/- 10.9 ng/ml, p = 0.023).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[ng] / [ml],52.5,117528,DB00918,Almotriptan
,11210405,Cmax,"Mean almotriptan Cmax was significantly higher following combination treatment with fluoxetine (52.5 +/- 11.9 ng/ml vs. 44.3 +/- 10.9 ng/ml, p = 0.023).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[ng] / [ml],44.3,117529,DB00918,Almotriptan
,11210405,AUC0-infinity,"Mean AUC0-infinity was not significantly affected by fluoxetine coadministration (353 +/- 55.7 ng.h/ml vs. 333 +/- 33.6 ng.h/ml, p = 0.059).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[h·ng] / [ml],353,117530,DB00918,Almotriptan
,11210405,AUC0-infinity,"Mean AUC0-infinity was not significantly affected by fluoxetine coadministration (353 +/- 55.7 ng.h/ml vs. 333 +/- 33.6 ng.h/ml, p = 0.059).",Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210405/),[h·ng] / [ml],333,117531,DB00918,Almotriptan
,12353056,absolute bioavailability,Almotriptan is well absorbed orally; its absolute bioavailability in humans is 70%.,"Almotriptan, a new anti-migraine agent: a review. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),%,70,123996,DB00918,Almotriptan
,12353056,elimination half-life,Its peak plasma levels are reached at 1 to 3 h after its administration; its elimination half-life is 3 to 4 h.,"Almotriptan, a new anti-migraine agent: a review. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),h,3 to 4,123997,DB00918,Almotriptan
,12463724,bioavailability,"After s.c. administration of almotriptan, the bioavailability was 100% with a time to maximum plasma concentration (tmax) of 5 to 15 minutes, whereas after oral administration, the bioavailability was about 70% with a tmax of 1.5 to 3.0 hours.","Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463724/),%,100,140990,DB00918,Almotriptan
,12463724,time to maximum plasma concentration (tmax),"After s.c. administration of almotriptan, the bioavailability was 100% with a time to maximum plasma concentration (tmax) of 5 to 15 minutes, whereas after oral administration, the bioavailability was about 70% with a tmax of 1.5 to 3.0 hours.","Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463724/),min,5 to 15,140991,DB00918,Almotriptan
,12463724,bioavailability,"After s.c. administration of almotriptan, the bioavailability was 100% with a time to maximum plasma concentration (tmax) of 5 to 15 minutes, whereas after oral administration, the bioavailability was about 70% with a tmax of 1.5 to 3.0 hours.","Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463724/),%,70,140992,DB00918,Almotriptan
,12463724,tmax,"After s.c. administration of almotriptan, the bioavailability was 100% with a time to maximum plasma concentration (tmax) of 5 to 15 minutes, whereas after oral administration, the bioavailability was about 70% with a tmax of 1.5 to 3.0 hours.","Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463724/),h,1.5 to 3.0,140993,DB00918,Almotriptan
,12463724,elimination half-life (t(1/2),"No significant differences were observed between administration routes in the elimination half-life (t(1/2), obtaining mean values ranging from 3.4 to 3.6 hours.","Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12463724/),h,3.4 to 3.6,140994,DB00918,Almotriptan
,22406349,peak plasma concentration (C(max)),The peak plasma concentration (C(max)) after 0.3h of 5mg/kg oral dose of almotriptan was determined to be 69.85 ng/mL.,"LC-ESI-MS/MS determination of in vivo metabolites of almotriptan in rat plasma, urine and feces: application to pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406349/),[ng] / [ml],69.85,159980,DB00918,Almotriptan
,16971345,absolute bioavailability,The absolute bioavailability was variable reflecting different degrees of absorption and first-pass metabolism (18.7-79.6%).,"Disposition and metabolism of almotriptan in rats, dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971345/),%,18.7-79.6,167346,DB00918,Almotriptan
,16971345,elimination half-life,The elimination half-life was short and ranged between 0.7 and 3 h.,"Disposition and metabolism of almotriptan in rats, dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16971345/),h,0.7 and 3,167347,DB00918,Almotriptan
,27757013,terminal elimination half-life in blood,Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours).,Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27757013/),h,26,182748,DB00918,Almotriptan
,22289113,area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],56.68,193499,DB00918,Almotriptan
,22289113,area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],78.49,193500,DB00918,Almotriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],56.68,193501,DB00918,Almotriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],22.39,193502,DB00918,Almotriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],78.49,193503,DB00918,Almotriptan
,22289113,maximum peak plasma concentration (C(max) ),"The geometric mean area under the plasma concentration-time curve from time 0 to infinity (AUC((0-∞)) ) (hours·ng/mL) and maximum peak plasma concentration (C(max) ) (ng/mL) were 56.68 (95% confidence interval [CI]: 48.60, 66.09) and 22.39 (95% CI: 17.90, 28.02), respectively, for the <40kg group and 78.49 (95% CI: 68.93, 89.38) and 22.27 (95% CI: 18.43, 26.92), respectively, for the ≥40kg group.",Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22289113/),[ng] / [ml],22.27,193504,DB00918,Almotriptan
,22896823,limit of detection (LOD),"The limit of detection (LOD) and limit of quantification (LOQ) for Almotriptan were 0.2 pg/mL and 0.5 ng/mL, respectively.",Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22896823/),[pg] / [ml],0.2,198842,DB00918,Almotriptan
,22896823,limit of quantification (LOQ),"The limit of detection (LOD) and limit of quantification (LOQ) for Almotriptan were 0.2 pg/mL and 0.5 ng/mL, respectively.",Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22896823/),[ng] / [ml],0.5,198843,DB00918,Almotriptan
,22896823,recovery,The mean recovery of drug and internal standard from human plasma was 92.12 ± 4.32% and 89.62 ± 6.32%.,Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22896823/),%,92.12,198844,DB00918,Almotriptan
,22896823,recovery,The mean recovery of drug and internal standard from human plasma was 92.12 ± 4.32% and 89.62 ± 6.32%.,Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22896823/),%,89.62,198845,DB00918,Almotriptan
,15762767,half-life,The compound has a half-life of approximately 3 hours.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),h,3,226151,DB00918,Almotriptan
,15762767,absolute bioavailability,Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69.1%.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),%,69.1,226152,DB00918,Almotriptan
,12723463,AUC,"Ketoconazole coadministration increased mean almotriptan AUC and Cmax from 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively.",Interaction between ketoconazole and almotriptan in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[h·ng] / [ml],312 to 490,238911,DB00918,Almotriptan
,12723463,Cmax,"Ketoconazole coadministration increased mean almotriptan AUC and Cmax from 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively.",Interaction between ketoconazole and almotriptan in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[ng] / [ml],52.6 to 84.5,238912,DB00918,Almotriptan
,12723463,oral clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],40,238913,DB00918,Almotriptan
,12723463,oral clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],26,238914,DB00918,Almotriptan
,12723463,renal clearance,"Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h).",Interaction between ketoconazole and almotriptan in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723463/),[l] / [h],16.4 to 13.8,238915,DB00918,Almotriptan
,30033394,Brain/blood ratios,"Results revealed rapid ALM brain delivery of the optimized formula; Brain/blood ratios at 10 min. for NF (SLNs based IN in-situ gel), ND (Free ALM IN in situ gel) and ALM i.v. (ALM IV solution) were 0.89, 0.19 and 0.31, respectively.","A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30033394/),,0.89,253565,DB00918,Almotriptan
,30033394,Brain/blood ratios,"Results revealed rapid ALM brain delivery of the optimized formula; Brain/blood ratios at 10 min. for NF (SLNs based IN in-situ gel), ND (Free ALM IN in situ gel) and ALM i.v. (ALM IV solution) were 0.89, 0.19 and 0.31, respectively.","A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30033394/),,0.19,253566,DB00918,Almotriptan
,30033394,Brain/blood ratios,"Results revealed rapid ALM brain delivery of the optimized formula; Brain/blood ratios at 10 min. for NF (SLNs based IN in-situ gel), ND (Free ALM IN in situ gel) and ALM i.v. (ALM IV solution) were 0.89, 0.19 and 0.31, respectively.","A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30033394/),,0.31,253567,DB00918,Almotriptan
,21736929,transdermal flux,"Under these experimental conditions, the transdermal flux of the drug increased 411-fold with respect to passive diffusion, reaching 264±24μg/cm(2)h (mean±SD).",Effect of iontophoresis on in vitro transdermal absorption of almotriptan. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21736929/),[μg] / [cm(2)h],264,258639,DB00918,Almotriptan
